TrialBlood advances2021

Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma.

Luciano J Costa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.